- Amended Report of Foreign Issuer (6-K/A)
May 07 2010 - 10:13AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Amendment No. 1 to
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER
THE
SECURITIES
EXCHANGE ACT OF 1934
For
the month of May 2010
Commission
file number 0-30752
ÆTERNA
ZENTARIS INC.
1405,
boul. du Parc-Technologique
Québec,
Québec
Canada,
G1P 4P5
(Address of
principal executive offices)
Indicate by check mark
whether the registrant files or will file annual reports under cover of Form 20-F
or Form 40-F.
Form 20-F
x
Form 40-F
o
Indicate by check mark if
the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1):
o
Indicate by check mark if
the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7):
o
Indicate by check mark
whether the registrant by furnishing the information contained in this Form is
also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under
the Securities Exchange Act of 1934. Yes
o
No
x
If Yes is marked,
indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
82- .
EXPLANATORY
NOTE
Æterna Zentaris Inc. is
filing this Amendment No. 1 to its Current Report on Form 6-K dated March 30,
2010 solely to re-file Exhibit 99.1 and to amend the Documents Index
contained therein. No other changes have
been made.
DOCUMENTS
INDEX
Documents Description
*99.1
|
|
License and Cooperation
Agreement for Perifosine by and between Zentaris AG and AOI Pharma, Inc.
dated September 18, 2002
|
99.2
|
|
Addendum agreement to
License and Cooperation Agreement for Perifosine by and between Zentaris AG
and AOI Pharma, Inc. dated December 3, 2003
|
99.3
|
|
First Amendment to
License and Cooperation Agreement for Perifosine by and between Aeterna
Zentaris GmbH and AOI Pharma Inc., dated November 29, 2007
|
* Filed herewith.
Confidential treatment requested as to
certain portions, which portions are omitted and filed separately with the Securities
and Exchange Commission.
2
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
|
|
ÆTERNA ZENTARIS INC.
|
|
|
|
|
|
|
|
|
|
|
Date:
|
May 7, 2010
|
|
By:
|
/s/ Dennis Turpin
|
|
|
|
|
Dennis Turpin
|
|
|
|
|
Senior Vice President
and Chief Financial Officer
|
3
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2023 to Jul 2024